ArticleOncoimmunology2015
A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with
Open access · goldAbstract read
In one paragraph
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Effectiveness and Safety of Therapeutic Vaccines for Precancerous Cervical Lesions: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Trial
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence.medRxiv : the preprint server for health sciences · 2026Article
- Advances in immunotherapy for HPV-associated malignancies: emerging strategies and clinical progress.Frontiers in immunology · 2026Review
- Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses.NPJ vaccines · 2025Article
- Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials.Current oncology (Toronto, Ont.) · 2025Review
- The evaluation of a novel multi-epitope vaccine against human papillomavirus and Candida albicans.Journal, genetic engineering & biotechnology · 2025Article
- Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review.Human vaccines & immunotherapeutics · 2024Review
- Tumor Antigens beyond the Human Exome.International journal of molecular sciences · 2024Review
- Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions.Life (Basel, Switzerland) · 2024Review
- Review
- Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives.Current issues in molecular biology · 2023Review
- Review
- Review
- Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer.Cancers · 2022Review
- Governing HPV-related carcinoma using vaccines: Bottlenecks and breakthroughs.Frontiers in oncology · 2022Review
- Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances.International journal of nanomedicine · 2022Review
- The association of cervicovaginal Langerhans cells with clearance of human papillomavirus.Frontiers in immunology · 2022Review
- Article
- Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus.Environmental science and pollution research international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 2 countries.
William W GreenfieldDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Shawna L StrattonCollege of Medicine; Translational Research Institute; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Rebecca S MyrickCollege of Medicine; Translational Research Institute; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Rita VaughnCollege of Medicine; Translational Research Institute; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Lisa M DonnalleyCollege of Medicine; Translational Research Institute; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Hannah N ColemanPathology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Maria MercadoPathology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Andrea M Moerman-HerzogPathology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Horace J SpencerBiostatistics; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Nancy R Andrews-CollinsDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Wilbur C HittDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Gordon M LowDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Nirvana A ManningDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Samantha S McKelveyDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Dora SmithDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Michael V SmithDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Amy M PhillipsDepartments of Obstetrics and Gynecology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
C Matthew QuickPathology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Susanne K JeffusPathology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Laura F HutchinsMedicine (Hematology-Oncology Division); University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Mayumi NakagawaPathology; University of Arkansas for Medical Sciences ; Little Rock, AR USA.
Arkansas Department of Agriculture · USTranslational Research Institute · AUCancer Research And Biostatistics · US
Funding
Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021
$21.5MUnderstanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-RenewalR01CA143130 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI NAKAGAWA, MAYUMI · 2010 to 2025
$10.0MArkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0MNCATS NIH HHS UL1 TR000039NCI NIH HHS R01 CA143130NIGMS NIH HHS P20 GM103625
Abstract
PubMed holds no abstract for this paper.
Indexed as
cervical intraepithelial neoplasiaclinical trialhuman papillomavirusT cellstherapeutic vaccine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.